Have Questions?

Global Headquarters

Tel: +44 (0)20 7377 0800
Fax: +44 (0)20 7349 5157

North America

Tel: 1-617-573-9450
Fax: 1-617-573-9542


Tel: +81 (0)80-1164-4754

Request a Demo

What our customers are saying

When I think of the future, I think of EvaluatePharma

Senior Director,
Global pharmaceutical company

EvaluateMedTech World Preview 2017, Outlook to 2022

Worldwide Medtech Sales Forecast to Reach $522 Billion by 2022 with a CAGR of 5.1% between 2016 and 2022

EvaluatePharma World Preview 2017 EvaluatePharma World Preview 2017 EvaluatePharma World Preview 2017

Download Report

The new edition of EvaluateMedTech World Preview 2017, Outlook to 2022 shows Medtronic was the leading medtech company in 2016 with sales of almost $30bn. They will retain the crown in 2022 with sales forecast to reach $37.7bn.

Our annual report highlights trends in medtech including: consensus sales forecasts of leading industry analysts by device area to 2022; the top 20 companies in 2022; R&D spend current and future; FDA approvals; M&A; venture financing; IPOs; and enterprise value.

Key Highlights

  • Total value of medtech M&A deals rises by a massive 178% in H1 2017
  • In vitro diagnostics is expected to remain the largest medtech segment in 2022 with annual sales of $70bn; Roche remains top player with expected sales of $12.8bn in 2022
  • Venture capital investment looks to be on track to at least match 2016’s total
  • Total value of medtech venture financing deals rises 56% in H1 2017 despite the number of deals falling by 11%

This analysis is based on in-depth consensus forecast models for the top 300 global medtech companies available within the EvaluateMedTech service.

Press Release | View Infographic | Report Executive Summary

Confirm your details on form below to download this report